University of Crete (UOC)
The role of adipose tissue T cells in tumor develοpment and response to immunotherapy
Abstract
dc:descriptionImmune checkpoint blockade (ICB) therapy, such as anti-CTLA4, anti-PD1 anti-PDL1, has rapidly transformed the treatment paradigm for various cancer types. However, most patients could not benefit from these immunotherapies due to primary and acquired drug resistance, underscoring the need to identify unrecognized mechanisms of immunotherapy resistance and response. This PhD dissertation focuses on these unrecognized mechanisms, putting emphasis on the adipose tissue (AT) and the bone marrow (BM).The AT possesses a diverse population of immune cells involved in inflammation and metabolic homeostasis, yet it’s role in anti-tumour immunity beyond the context of obesity remains unexplored. T lymphocytes, which are crucial for anti-tumor immunity and efficacy of ICB, reside in the AT, where they display distinct transcriptomic signatures and unique functions.Our work explores the contribution of AT T cells to anti-tumor immunity and how this influences immunotherapy outcome in the context of tumor developing at a site distant from the AT. The AT from breast-cancer patients contains more PD-1+ T cells compared to peripheral blood, similar to what observed in mice inoculated with B16.F10 melanoma cell line, positioning them as potential targets for ICB therapy. Flow Cytometry, Single Cell and TCR sequencing analyses, revealed that murine AT T cells are in large composed of Tissue Resident Memory T cells (TRM), exerting potent antitumor functions, unique metabolic profiles, and rapid cytokine production during murine tumor development compared to T cells found in tumour draining lymph nodes (tdLN). Tumor-associated T cell clones were identified within the AT of tumor-bearing mice, underlining its role in systemic immune surveillance. At the same time, common clones were identified between the AT T cells and tdLNs, highlighting the communication between the two tissues. In a novel transplantation experiment, AT transplant from wild-type mice into adaptive immunity deficient mice restrained tumor development, with donor AT cells infiltrating into the tumor microenvironment (TME). These findings were even more prominent in the presence of anti-PD1 treatment. Together, these data reveal the previously underappreciated antitumor abilities and increased sensitivity to PD-1 blockade of AT TRM cells.This PhD dissertation further unraveled intriguing data concerning additional effects of immunotherapy, beyond its impact on the AT, specifically on BM-residing cells. Analyses of the effect of anti-PD1, and anti-PDL1 treatment revealed significant reduction of myeloid-derived suppressor cells (MDSCs) frequencies in tumor-bearing mice, not only within the AT but also in the spleen, blood, and TME. Considering that MDSCs originate from BM hematopoietic progenitors, we formulated the hypothesis that ICB therapy might influence cancer-induced emergency myelopoiesis. Thus, to test this hypothesis, we investigated the effect of ICB treatment on Hematopoietic Stem and Progenitor Cells (HSPCs) with our findings revealing that anti-PDL1 in tumour-bearing mice drives their exit from quiescence and promotes their proliferation. Notably, disruption of the PDL1/PD1 axis induced transcriptomic reprogramming of HSPCs towards an inflammatory state in both Hodgkin lymphoma (HL) patients and tumour-bearing mice. Furthermore, transplantation of HSPCs isolated from antiPDL1-treated mice resisted cancer-induced emergency myelopoiesis as evidenced by the reduced generation of MDSCs compared to control-treated mice. These data reveal an underappreciated mechanism by which ICB therapies target the BM niche and suggest that reprogramming HSPCs can interfere with tumor-induced immune suppression. In summary, this works delineates mechanisms through which ICB therapy targets AT TRM cells and BM HSPCs, modulating both systemic and local anti-tumor immunity through targeting of different immune cells across different tissue compartments, paving the way to more comprehensive therapeutic strategies.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Boumpa, Athina
- Μπούμπα, Αθηνά
Subjects
dc:subject × 15Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/58261